Immupharma PLC recruiting in Europe for Lupus trial
Recruiting patients in Europe has now begun for the pivotal phase III trial of Lupuzor, the firm said.
Company
ImmuPharma PLC
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 15 of 16
Archive
Proactive news summary: Amur, Aureus, Forbidden, Purecircle and more...
Horse Hill off to the races, Forbidden technologies extends contract and PureCircle doubles earnings.
Immupharma confirms £8.4mln fundraise
Shares in ImmuPharma nudged higher as it confirmed it had raised a total £8.4mln to advance the potential blockbuster drug Lupuzor.
Immupharma updates on successful placing
Drug discovery firm ImmuPharma has raised £7.7mln from the previously announced fundraise and is due to receive a further £0.7mln from advance assurances.
Archive
Proactive news summary: Windar Photonics, 88 Energy, Metal Tiger, Egdon Resources and more.
Everything appears to being going to plan for 88 Energy in Alaska...
ImmuPharma passes landmark as phase III dosing starts
In all clinical trials will take place across 45 locations – 10 in America, the rest in Europe.
ImmuPharma raises £8.3mln to fund potential blockbuster
The company will use cash to fund its share of costs of developing Lupuzor, the potential blockbuster drug for autoimmune disease Lupus, which is undergoing phase III clinical trials.
Investments and investor services
Proactive news highlights: ANGLE, Motive Television, Utilitywise and more...
Weatherly International, Motif Bio and 88 energy also had news out on Tuesday
ImmuPharma rolling on rapidly with Lupuzor
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
ImmuPharma meeting brings together Lupus specialists
ImmuPharma was host to 70 investigators and senior coordinators from the US and Europe who will be involved in the pivotal phase-III trial of Lupuzor...
Risers & Fallers: Amur Minerals, Immupharma, Rosslyn Data and more...
Below are the main news-driven share price movements at 4pm
Investments and investor services
Markets: Oil stocks push FTSE100 lower
The FTSE100 ended the day almost 15 points lower to 6,223.
Investments and investor services
Proactive news highlights: IOG, Motif Bio, allergy Therapeutics, ReNeuron, Immupharma and more
Sunrise Resources, Optibiotix Health and ITM Power also had news out
Investments and investor services
Risers & Fallers: Immupharma, Kenmare, Pinnacle and more
Below are the main news-driven share price movements at 4pm.
Archive
Proactive news summary: Allergy Therapeutics, Berkeley Energy, Forbidden Technologies, Gemfields ...
Pride of place goes to Plethora Solutions, after Jim Mellon's Regent Pacific offered to take it over.
ImmuPharma spells out plans for phase III clinical trial
The study, being carried out with the help of clinical research firm Simbec-Orion, will take place at 45 different sites – 10 in the US, 35 in Europe.
Investments and investor services
Proactive news highlights: Venn Life Sciences, Optibiotix, Petropavlovsk, Mart, 88 Energy and more
Pharma companies and energy firms were in the news today...
ImmuPharma non-executive director bows out
Dr Ajay Agrawal is to step down with immediate effect
Archive
Proactive news highlights - Strategic Minerals, ServicePower, Bushveld Minerals, Iona Energy and Summit Therapeutics
If you're a fan of interim results statements, today was dedicated to you.